A Study of LY4175408 in Participants With Advanced Cancer (NCT07046923)
A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4175408, an Antibody Drug Conjugate Targeting Protein Tyrosine Kinase 7-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. Participation could last up to 4 years.
Who can join: Review the eligibility criteria below.
Location: Stanford Medicine Cancer Center — Stanford, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (27 Sites)
Showing the first 25 of 27 sites.
- Stanford Medicine Cancer Center — Stanford, California
- Florida Cancer Specialists - Lake Nona - Sarah Cannon Research Institute — Orlando, Florida
- Florida Cancer Specialists - Sarasota — Sarasota, Florida
- The University of Chicago Medical Center (UCMC) — Chicago, Illinois
- Community Health Network — Indianapolis, Indiana
- Massachusetts General Hospital — Boston, Massachusetts
- Washington University — St Louis, Missouri
- John Theurer Cancer Center At Hackensack UMC — Hackensack, New Jersey
- Columbia University — New York, New York
- David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center — New York, New York
- The Ohio State University (OSU) Wexner Medical Center — Columbus, Ohio
- Sarah Cannon Research Institute — Nashville, Tennessee
- MD Anderson Cancer Center — Houston, Texas
- START Mountain Region — West Valley City, Utah
- NEXT Virginia — Fairfax, Virginia
- West China Hospital, Sichuan University — Chengdu,
- Shanghai East Hospital, Tongji University — Shanghai,
- Tongji Hospital - Tongji Medical College of HUST — Wuhan,
- Centre Leon Berard — Lyon,
- Institut Gustave Roussy — Villejuif,
- Kyoto University Hospital — Kyoto,
- National Cancer Center Hospital — Tokyo,
- Cancer Institute Hospital of JFCR — Tokyo,
- Severance Hospital, Yonsei University Health System — Seoul,
- Samsung Medical Center — Seoul,
📞 Contact the Study Coordinator
Phone: (317) 615-4559
Email: LillyTrials@Lilly.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Carcinoma, Non-Small-Cell Lung
- MYLUNG Consortium Study Protocol 2 — Daphne, Alabama
- A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) — Des Moines, Iowa
- THIO Sequenced With Cemiplimab in Advanced NSCLC — Birmingham, Alabama
- A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions — Duarte, California
- Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study — La Jolla, California
- A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) — Los Angeles, California
Explore by condition: All Carcinoma, Non-Small-Cell Lung clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.